AIM
MDCO

Alambic Investment Management’s Medicines Co MDCO Stock Holding History

Alambic Investment Management’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4,865
Closed -$238K – 730
2017
Q1 		$238K Buy
+4,865
New +$222K 0.03% 548

Other funds holding MDCO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CM
Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Alambic Investment Management's MDCO Position: Q2 2017 in Review

Alambic Investment Management sold out of Medicines Co (MDCO) in Q2 2017, closing a stake of 4,865 shares — an estimated $238K sold.

Alambic Investment Management first reported a position in MDCO in Q1 2017 and held it in 1 quarter. The position peaked at $238K in Q1 2017. 202 funds tracked by Wall St. Rank hold MDCO as of Q2 2017.

  • Alambic Investment Management reported no remaining Medicines Co position as of Q2 2017 after selling out during the quarter.
  • Alambic Investment Management sold 4,865 Medicines Co shares in Q2 2017, an estimated $238K.
  • Alambic Investment Management first reported a position in Medicines Co in Q1 2017 and held it in 1 quarter.
  • Alambic Investment Management's Medicines Co position peaked at $238K in Q1 2017.
  • 202 funds tracked by Wall St. Rank held Medicines Co as of Q2 2017.

Based on Alambic Investment Management's 13F filing for Q2 2017, filed 14 Aug 2017.